{"id":241414,"title":"Considerations for the use of nirmatrelvir/ritonavir (brand name Paxlovid) to treat COVID-19 - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T15:43:41.888000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/considerations-nirmatrelvir-ritonavir-paxlovid.html","snippet":"Considerations for the use of nirmatrelvir/ritonavir (brand name Paxlovid) to treat COVID-19 - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du Canada Search Search Canada.ca Search Menu Main Menu Jobs and the workplace…","rawSnapshotUrl":"/api/snapshots/raw/241414","browseUrl":"https://replay.healtharchive.ca/job-1/20250418154341/https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/considerations-nirmatrelvir-ritonavir-paxlovid.html#ha_snapshot=241414","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}